Show source-provided references
1. Clinical, Therapeutic, and Prognostic Experience in Patients With Glioblastoma
2. Roda, D., Veiga, P., Melo, J.B., Carreira, I.M., and Ribeiro, I.P. (2024). Principles in the Management of Glioblastoma. Genes, 15.
10.3390/genes15040501 ↗3. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
10.1093/neuonc/nox175 ↗7. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC
10.1002/ijc.24522 ↗10. MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme
10.1038/cddis.2012.134 ↗11. MicroRNA-10b mediates TGF-beta1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition
10.3892/ijo.2017.3947 ↗12. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: First steps toward the clinic
10.15252/emmm.201505495 ↗17. Stepanov, G., Zhuravlev, E., Shender, V., Nushtaeva, A., Balakhonova, E., Mozhaeva, E., Kasakin, M., Koval, V., Lomzov, A., and Pavlyukov, M. (2018). Nucleotide Modifications Decrease Innate Immune Response Induced by Synthetic Analogs of snRNAs and snoRNAs. Genes, 9.
10.3390/genes9110531 ↗19. Meng, Z., and Lu, M. (2017). RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?. Front. Immunol., 8.
10.3389/fimmu.2017.00331 ↗20. Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model
10.18632/oncotarget.25135 ↗23. Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a “Personalized” Anti-microRNA Therapy
10.1021/acs.molpharmaceut.6b00388 ↗24. Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells
10.1080/03639045.2017.1391835 ↗25. Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells
10.1080/03639045.2016.1200069 ↗26. Zhang, Y., Rabinovsky, R., Deforzh, E., Kobayashi, A., Kuzkina, A., Varghese, J.F., Rai, D., Korecka, J.A., Khurana, V., and Murugaiyan, G. (2025). Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma. Neuro Oncol., noaf162.
10.1093/neuonc/noaf162 ↗28. Chen, M., Kim, B., Robertson, N., Mondal, S.K., Medarova, Z., and Moore, A. (2023). Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells. Front. Mol. Biosci., 10.
10.3389/fmolb.2023.1179343 ↗29. Savan, N.A., Saavedra, P.V., Halim, A., Yuzbasiyan-Gurkan, V., Wang, P., Yoo, B., Kiupel, M., Sempere, L., Medarova, Z., and Moore, A. (2022). Case report: MicroRNA-10b as a therapeutic target in feline metastatic mammary carcinoma and its implications for human clinical trials. Front. Oncol., 12.
10.3389/fonc.2022.959630 ↗30. Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis
10.1038/onc.2012.173 ↗31. Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer
10.1158/0008-5472.CAN-15-0888 ↗32. Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer
10.1038/srep45060 ↗33. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma
10.1038/s41588-018-0105-0 ↗34. Optimization of Glioblastoma Mouse Orthotopic Xenograft Models for Translational Research
35. The clinical significance of radiological changes associated with gliadel implantation in patients with recurrent high grade glioma
10.1038/s41598-022-27128-4 ↗39. Novel membrane-permeable contrast agent for brain tumor detection by MRI
10.1002/mrm.22216 ↗43. Stepwise detection and evaluation reveal miR-10b and miR-222 as a remarkable prognostic pair for glioblastoma
10.1038/s41388-019-0867-6 ↗44. Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
45. Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10
47. Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer
10.1186/s12645-021-00089-5 ↗48. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent
10.1097/01.rli.0000197669.80475.dd ↗49. Chelate-free metal ion binding and heat-induced radiolabeling of iron oxide nanoparticles
10.1039/C4SC02778G ↗50. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: Implications for magnetic resonance imaging
10.1007/s00441-004-0884-8 ↗51. Long-term biodistribution and biocompatibility investigation of dextran-coated magnetite nanoparticle using mice as the animal model
10.1166/jbn.2012.1376 ↗52. Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: In vivo study
57. Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways
10.1158/0008-5472.CAN-16-1571 ↗58. MGMT promoter methylation status testing to guide therapy for glioblastoma: Refining the approach based on emerging evidence and current challenges
10.1093/neuonc/noy132 ↗59. Yoo, B., Greninger, P., Stein, G.T., Egan, R.K., McClanaghan, J., Moore, A., Benes, C.H., and Medarova, Z. (2018). Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin. PLoS ONE, 13.
10.1371/journal.pone.0201046 ↗60. Tumor microenvironment in glioblastoma: Current and emerging concepts